University of Pennsylvania
About University of Pennsylvania
The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League, research university located in Philadelphia. Incorporated as The Trustees of the University of Pennsylvania, Penn is one of 14 founding members of the Association of American Universities and one of the nine original Colonial Colleges. Penn claims to be the oldest university in the United States of America, and is consistently ranked as one of the world's most prestigious universities.
40th in USA
35th in USA
35th in USA
128th in USA
Journal Editors at University of Pennsylvania
Reviewers from University of Pennsylvania
I am a habilitated doctor at the Westphalian Wilhelms University and a group leader at the Max Planck Institute for Molecular Biomedicine, both in Muenster (NRW, Germany). I received my education in reproductive biology and am a certified biologist as well as a laboratory animal scientist. I studied and trained at the University of Pavia (Italy), at the Rigshospitalet (Denmark) and at the University of Pennsylvania (USA), where I developed a keen interest in the mammalian oocyte with emphasis on the ooplasm’s ability to convert somatic nuclei from a differentiated to a toti/pluripotential state of gene expression (‘reprogramming’). In my research, I have shown that oocyte-mediated nuclear reprogramming in mice is an orderly process that is amenable to control by cell-cell interactions (embryo aggregation) and in vitro culture conditions (culture media as epigenetic modifiers). Currently my team investigates the genetic and epigenetic factors that influence cell and nuclear identity in mouse embryos, such as: 1) oocytic i.e. maternal factors (Reproduction 148:55-72, 2014); 2) environmental factors e.g. culture conditions (Human Reproduction 27:2627-2640, 2012). As a respected member of the nuclear transfer community I have published over 40 peer-reviewed publications in prime journals and have written numerous book chapters on nuclear reprogramming by oocytes and on embryonic stem cells. I received support from the Deutsche Forschungsgemeinschaft (DFG) and from the Max Planck Gesellschaft (MPG).
Casey is an assistant professor in the Department of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine at the University of Pennsylvania. His lab develops deep learning methods that integrate distinct large-scale datasets to extract the rich and intrinsic information embedded in such integrated data. This approach reveals underlying principles of an organism’s genetics, its environment, and its response to that environment. Extracting this key contextual information reveals where the data’s context doesn’t fit existing models and raises the questions that a complete collection of publicly available data indicates researchers should be asking. In addition to developing deep learning methods for extracting context, a core mission of his lab is bringing these capabilities into every molecular biology lab. Before starting the Integrative Genomics Lab in 2012, Casey earned his Ph.D. for his study of gene-gene interactions in the field of computational genetics from Dartmouth College in 2009 and moved to the Lewis-Sigler Institute for Integrative Genomics at Princeton University where he worked as a postdoctoral fellow from 2009-2012. The overarching theme of his work has been the development and evaluation of methods that acknowledge the emergent complexity of biological systems.
I obtained his undergraduate degree from Princeton University and my medical degree from the University of Pennsylvania. I completed general surgery training at the Hospital of the University of Pennsylvania followed by subspecialty training in Surgical Oncology at the Memorial Sloan-Kettering Cancer Center. In 2007, I joined the faculty of the University of California Davis School of Medicine in the Department of Surgery, Division of Surgical Oncology. My research focuses on sarcoma cancer stem cells as a mechanism of resistance to standard anti-proliferative anti-cancer therapies, and I am studying natural killer (NK) cellular immunotherapy as a mechanism to target the cancer stem cell population following standard cancer treatments such as radiotherapy. My goal is to translate these studies to early phase clinical trials for canine and human patients with advanced bone and soft tissue sarcomas. I also perform health services research analyzing short- and long-term outcomes in soft tissue sarcoma patients undergoing combined modality therapy. I currently hold the title of Associate Professor.